Evidence map›Paper›PMID 41034556›Full record

ArticleCommunications biology2025

A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality control.

Ziyuan Wang, Mei-Juan Tu, Ziyang Liu, Katherine K Wang, Yinshan Fang, Ning Hao, Hao Helen Zhang, Jianwen Que, Xiaoxiao Sun, Ai-Ming Yu and 1 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ziyuan Wang *Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-2476-2929
Mei-Juan Tu *Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.
Ziyang Liu *Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA.
Katherine K WangDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA.ORCID http://orcid.org/0009-0006-2069-5665
Yinshan FangDepartment of Medicine, Columbia Center for Human Development, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9249-4498
Ning HaoStatistics and Data Science GIDP, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0002-3104-5370
Hao Helen ZhangStatistics and Data Science GIDP, University of Arizona, Tucson, AZ, USA.
Jianwen QueDepartment of Medicine, Columbia Center for Human Development, Columbia University Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6540-6701
Xiaoxiao SunStatistics and Data Science GIDP, University of Arizona, Tucson, AZ, USA. xiaosun@arizona.edu.ORCID http://orcid.org/0000-0003-1438-1951
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, USA. aimyu@ucdavis.edu.ORCID http://orcid.org/0000-0003-1441-4012
Hongxu DingDepartment of Pharmacy Practice and Science, University of Arizona, Tucson, AZ, USA. hongxuding@arizona.edu.ORCID http://orcid.org/0000-0002-7846-9744

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Novel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7M
Novel biologic RNA molecules to modulate HCC metabolismR01CA291771 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2024 to 2026
$2.4M
Improve Lung Regeneration Through Targeting Tuft Cells Following Viral InfectionR01HL159675 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QUE, JIANWEN · 2021 to 2024
$2.4M
Cell Fate Regulation in Esophageal Progenitor CellsR01DK132251 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LU, CHAO, QUE, JIANWEN · 2022 to 2025
$2.3M
Training Program in PharmacologyT32GM144303 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Donald M Bers, JOHANNES W HELL · 2022 to 2026
$2.1M
Supplement: Recombinant microRNAs in xenobiotic metabolism and dispositionR35GM140835 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2021 to 2025
$2.0M
VEGF/KDR Signaling in Airway Epithelial Regeneration and DiseaseR01HL152293 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QUE, JIANWEN · 2021 to 2024
$2.0M
Recombinant microRNAs in xenobiotic and nutrient dispositionR01CA253230 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Meijuan Tu · 2021 to 2026
$1.7M
Post-transcriptional modification in esophageal basal cells.R01DK144271 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jianwen Que · 2025 to 2026
$1.6M
Tuft Cells Modulate Macrophage Response Following Lung Viral InfectionR21AI163753 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QUE, JIANWEN · 2022 to 2023
$446k
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225958NCI NIH HHS R01 CA253230NCI NIH HHS R01 CA291771NHLBI NIH HHS R01 HL152293NHLBI NIH HHS R01 HL159675NIAID NIH HHS R21 AI163753NIDDK NIH HHS R01 DK132251NIDDK NIH HHS R01 DK144271NIGMS NIH HHS R35 GM140835NIGMS NIH HHS T32 GM144303
6 · The paper itself

Abstract

Nucleotide modifications deviate nanopore sequencing readouts, therefore generating artifacts during the basecalling of sequence backbones. Here, we present a reference-guided, iterative approach to polish modification-disturbed basecalling results. We show that such an approach is uniquely suitable for training biomolecule-specific high-accuracy basecallers, by improving the basecalling of both artificially-synthesized and real-world molecules. With demonstrated efficacy and reliability, we exploit the approach to precisely basecall therapeutic RNAs consisting of artificial or natural modifications. We first analyzed vaccine mRNAs, which are artificially modified to promote stability and reduce immunogenicity. Specifically, we quantified the sequence purity and integrity, the two most important quality metrics to be controlled during mRNA vaccine production. We also analyzed BioRNAs, which are human tRNA-based carriers for therapeutic RNA interference (RNAi) agents. Specifically, we examined modification hotspots, which are naturally incorporated in vivo during BioRNA production and essential for therapeutic efficacy. Our analysis expands the scope of therapeutic RNA quality control, from the conventional sequence-level to the current modification status-level.

Indexed as

Nanopore SequencingRNA, MessengerSequence Analysis, RNAHumansmRNA VaccinesQuality ControlmRNA VaccinesRNA, Messenger

Identifiers

PMID41034556
PMCPMC12488850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.